Intranasal Ketamine + Dexmedetomidine for Procedural Sedation

(Ketodex Trial)

Recruiting in Palo Alto (17 mi)

Overseen by Naveen Poonai, MD

Age: < 18

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Recruiting

Sponsor: Lawson Health Research Institute

Disqualifiers: Schizophrenia, Psychosis, Hypertension, others

No Placebo Group

Prior Safety Data

Approved in 5 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial tests a new way to help children with broken bones feel less pain during treatment. Instead of using a painful method, doctors will give a mix of two medications through the nose. This method aims to make the experience less distressing and more comfortable for children.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

What data supports the effectiveness of the drug combination of intranasal ketamine and dexmedetomidine for procedural sedation?

Research shows that intranasal ketamine is effective for sedation in children, as seen in studies where it was used alone or with other drugs like midazolam for dental procedures and emergency department settings. This suggests that ketamine, as part of a combination, could be effective for procedural sedation. ^{1 2 3 4 5}

Is intranasal ketamine and dexmedetomidine safe for sedation in humans?

Intranasal ketamine and dexmedetomidine have been studied for sedation in children, showing that they are generally safe with minor adverse events. The combination may lead to a longer recovery time compared to dexmedetomidine alone, but both options are effective for sedation. ^{1 4 5 6 7}

How is the drug combination of intranasal ketamine and dexmedetomidine unique for procedural sedation?

The combination of intranasal ketamine and dexmedetomidine is unique because it offers a novel approach to procedural sedation, potentially improving onset time and maintaining stable heart function while being administered through the nose, which is less invasive than traditional methods. ^{8 9 10 11 12}

Research Team

Naveen Poonai, MD

Principal Investigator

Western University

Eligibility Criteria

This trial is for children aged 4-17 with orthopedic injuries like forearm fractures or dislocations needing sedation, weighing up to 60 kg. They must be able to follow the study's procedures and have no severe health issues like heart disease, uncontrolled hypertension, or cognitive impairments that prevent consent.

Inclusion Criteria

I have had a dislocated shoulder or elbow.

Your fracture is not severe or very short.

I am undergoing a painful medical procedure.

Exclusion Criteria

American Society of Anesthesiologists (ASA) class 3 or greater;

I have obstructive sleep apnea.

Your doctor has determined that your heart or blood pressure is not stable.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive intranasal dexmedetomidine plus ketamine for procedural sedation during closed reduction of fractures

4 hours

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including adverse effects and satisfaction

72 hours

Treatment Details

Interventions

• Dexmedetomidine (Alpha-2 Adrenergic Agonist)
• Ketamine (NMDA Receptor Antagonist)

Trial Overview The trial tests intranasal dexmedetomidine plus ketamine (IN Ketodex) against IV ketamine for sedation in kids during bone setting. It aims to see if IN Ketodex can provide deep enough sedation without the pain of an IV line.

Participant Groups

Group I: IN Ketodex (D4K2) Experimental Treatment 1 Intervention

Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL

Group II: IN Ketodex (D3K3) Experimental Treatment 1 Intervention

Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL

Group III: IN Ketodex (D2K4) Experimental Treatment 1 Intervention

Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL

Group IV: IV Ketamine Active Control 1 Intervention

Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares

Ketamine is already approved in Canada for the following indications:

Approved in Canada as Spravato for:

• Treatment-resistant depression

Who Is Running the Clinical Trial?

Lawson Health Research Institute

Lead Sponsor

Trials

684

Recruited

432,000+

Dr. Michael Strong

Lawson Health Research Institute

Chief Medical Officer

MD

Roy Butler

Lawson Health Research Institute

Chief Executive Officer

PhD in Health Sciences

Naveen Poonai

Lead Sponsor

Trials

3

Recruited

830+

Findings from Research

Intranasal (IN) ketamine is a safe and effective alternative for providing analgesia and anxiolysis in pediatric emergency department patients, with 100% provider comfort and high satisfaction scores (90 out of 100).

The use of IN ketamine resulted in a significantly shorter emergency department length of stay (mean 237.9 minutes) compared to traditional intravenous sedation methods (mean 332.4 minutes), while maintaining a low rate of minor adverse events (6%).

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Use of Intranasal Ketamine in Pediatric Patients in the Emergency Department. Guthrie, AM., Baum, RA., Carter, C., et al.[2023]

Intravenous (i.v.) ketamine can be safely administered by emergency physicians to children for procedures, with only minor adverse effects such as transient apnea and mild agitation observed in a study of 156 cases over 9 years.

The sedation characteristics of i.v. ketamine are comparable to those of intramuscular (i.m.) ketamine, indicating that both routes can be effectively used for pediatric sedation in emergency settings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Intravenous ketamine for pediatric sedation in the emergency department: safety profile with 156 cases. Green, SM., Rothrock, SG., Harris, T., et al.[2022]

Intranasal dexmedetomidine alone is as effective as a combination of dexmedetomidine and ketamine for sedating children during dental procedures, with similar levels of quiet behavior observed in both groups.

Using dexmedetomidine alone resulted in fewer adverse events and a faster recovery time compared to the combination with ketamine, making it a safer option for outpatient pediatric sedation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Intranasal Dexmedetomidine Compared to a Combination of Intranasal Dexmedetomidine with Ketamine for Sedation of Children Requiring Dental Treatment: A Randomized Clinical Trial. Sado-Filho, J., Corrêa-Faria, P., Viana, KA., et al.[2021]

Intranasal dexmedetomidine (D) and esketamine (K) are both effective for moderate sedation in uncooperative pediatric dental patients, with a study involving 150 children aged 3-10 years.

Esketamine (0.5 mg/kg) and the highest dose of dexmedetomidine (2.0 µg/kg) provided faster sedation onset and lower pain scores compared to lower doses of dexmedetomidine, indicating their potential for better sedation management.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison between dexmedetomidine and esketamine in pediatric dentistry surgery. Xin, N., Xu, H., Yue, C.[2022]

A systematic review of 10 randomized controlled trials involving pediatric patients found no significant differences in the efficacy of intranasal ketamine compared to intranasal dexmedetomidine for sedation during procedures, indicating that neither medication was clearly superior for outcomes like parental separation or mask acceptance.

However, intranasal ketamine was associated with a higher incidence of nausea and vomiting, while intranasal dexmedetomidine led to more cases of bradycardia, suggesting that safety profiles may influence clinical choices between these two premedication options.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and safety of intranasal ketamine compared with intranasal dexmedetomidine as a premedication before general anesthesia in pediatric patients: a systematic review and meta-analysis of randomized controlled trials. Dwivedi, P., Patel, TK., Bajpai, V., et al.[2022]

This study will evaluate the efficacy and safety of an intranasal combination of dexmedetomidine and ketamine for sedation in children under 7 years old, comparing it to the commonly used oral chloral hydrate in a randomized controlled trial involving 136 participants.

The primary goal is to determine how quickly each method achieves adequate sedation within 15 minutes, along with assessing sedation duration, failure rates, and any adverse effects, which will help establish the best sedation practice for pediatric patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Two-center randomized controlled trial comparing oral chloral hydrate and intranasal combination of dexmedetomidine and ketamine for procedural sedation in children: study protocol. Jang, YE., Joo, EY., Lee, JH., et al.[2023]

References

1. Singapore pubmed.ncbi.nlm.nih.gov

A comparative evaluation of intranasal midazolam, ketamine and their combination for sedation of young uncooperative pediatric dental patients: a triple blind randomized crossover trial. [2019]

2. France pubmed.ncbi.nlm.nih.gov

S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. [2016]

3. United States pubmed.ncbi.nlm.nih.gov

Randomized clinical trial on the efficacy of intranasal or oral ketamine-midazolam combinations compared to oral midazolam for outpatient pediatric sedation. [2020]

4. United States pubmed.ncbi.nlm.nih.gov

Use of Intranasal Ketamine in Pediatric Patients in the Emergency Department. [2023]

5. France pubmed.ncbi.nlm.nih.gov

Oral transmucosal ketamine: an effective premedication in children. [2019]

6. United States pubmed.ncbi.nlm.nih.gov

Intravenous ketamine for pediatric sedation in the emergency department: safety profile with 156 cases. [2022]

7. Switzerland pubmed.ncbi.nlm.nih.gov

Intranasal Dexmedetomidine Compared to a Combination of Intranasal Dexmedetomidine with Ketamine for Sedation of Children Requiring Dental Treatment: A Randomized Clinical Trial. [2021]

8. France pubmed.ncbi.nlm.nih.gov

Analysis of 17 948 pediatric patients undergoing procedural sedation with a combination of intranasal dexmedetomidine and ketamine. [2019]

9. China pubmed.ncbi.nlm.nih.gov

Comparison between dexmedetomidine and esketamine in pediatric dentistry surgery. [2022]

10. United States pubmed.ncbi.nlm.nih.gov

Efficacy and safety of intranasal ketamine compared with intranasal dexmedetomidine as a premedication before general anesthesia in pediatric patients: a systematic review and meta-analysis of randomized controlled trials. [2022]

11. England pubmed.ncbi.nlm.nih.gov

Two-center randomized controlled trial comparing oral chloral hydrate and intranasal combination of dexmedetomidine and ketamine for procedural sedation in children: study protocol. [2023]

12. England pubmed.ncbi.nlm.nih.gov

Intravenous ketamine plus midazolam is superior to intranasal midazolam for emergency paediatric procedural sedation. [2019]